natgillin/translations-raw huggingface dataset:
Following intravenous administration, choriogonadotropin alfa is distributed to the extracellular fluid space with a distribution half-life of around 4.5 hours. 
Po intravenski uporabi se horiogonadotropin alfa porazdeli v zunajceličnem prostoru s porazdelitvenim razpolovnim časom približno 4,5 ure.
• Ovitrelle is intended for subcutaneous use that means given by injection under the skin. 
• Zdravilo Ovitrelle je namenjeno za subkutano uporabo, kar pomeni, da se injicira pod kožo.
If too much Ovitrelle is used, there is a possibility that ovarian hyperstimulation syndrome may occur. 
Če uporabite preveč zdravila Ovitrelle, se lahko pojavi sindrom hiperstimulacije jajčnikov.
Do not use Ovitrelle if you are pregnant or breast-feeding. 
Ne uporabljajte zdravila Ovitrelle, če ste noseči ali dojite.
If you forget to use Ovitrelle If you forget to use Ovitrelle, please talk to your doctor as soon as you notice. 
Če ste pozabili uporabiti zdravilo Ovitrelle Če pozabite uporabiti zdravilo Ovitrelle, se takoj, ko je mogoče, posvetujte z zdravnikom.
Mild to severe hypersensitivity reactions including anaphylactic reactions and shock Psychiatric disorders 
blaga do huda preobčutljivostna reakcija, vključno z anafilaktičnimi reakcijami in šokom
Do not use Ovitrelle 
Ne uporabljajte zdravila Ovitrelle
Any unused solution must be discarded. 
Morebiti neuporabljeno raztopino morate zavreči.
When undergoing Assisted Reproductive Techniques, the risk of having a multiple pregnancy is related to the number of fertilised eggs or embryos placed inside you. 
Pri postopkih asistirane reprodukcije je tveganje za večplodno nosečnost povezano s številom prenesenih oplojenih jajčec ali embrijev.
Only clear solution without particles should be used. 
Uporabljati smete samo bistro raztopino brez delcev.
In comparative clinical trials, administration of a dose of 250 micrograms of Ovitrelle was as effective as 5,000 IU and 10,000 IU of urinary hCG in inducing final follicular maturation and early luteinisation in assisted reproductive techniques, and as effective as 5,000 IU of urinary hCG in ovulation induction. 
V primerjalnih kliničnih raziskavah je bil 250 mikrogramski odmerek zdravila Ovitrelle enako učinkovit pri indukciji dokončnega folikelskega dozorevanja in zgodnje luteinizacije v postopkih asistirane reprodukcije kot 5.000 i.e. in 10.000 i.e. urinskega hCG, ovulacijo pa je induciral enako učinkovito kot 5.000 i.e. urinskega hCG.
Choriogonadotropin alfa is similar to a hormone found naturally in your body called ‘chorionic gonadotropin', which is involved in reproduction and fertility. 
Horiogonadotropin alfa je podoben naravnemu človeškemu hormonu, imenovanem "horionski gonadotropin", ki sodeluje pri razmnoževanju in plodnosti.
• In case the dose display doesn't show 0, please contact your doctor or pharmacist. 
• V primeru, da v prikazu odmerka ni številke "0", se posvetujte z zdravnikom ali farmacevtom.
This medicine contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially “sodiumfree”. 
To zdravilo vsebuje manj kot 1 mmol (23 mg) natrija na odmerek, kar v bistvu pomeni "brez natrija".
Manufacturer Merck Serono S.p.A., Via delle Magnolie 15, 70026 Modugno (Bari), Italy 
Izdelovalec Merck Serono S.p.A., Via delle Magnolie 15, 70026 Modugno (Bari), Italija
3.2 Prepare your needle for Injection 
3.2 Pripravite injekcijsko iglo za injiciranje
Therefore, if signs of ovarian hyperstimulation occur such as serum estradiol level > 5,500 pg/mL (20,000 pmol/L) and/or when there are 30 or more follicles in total, it is recommended to withhold hCG administration and the patient be advised to refrain from coitus or to use barrier contraceptive methods for at least 4 days. 
Zato se pri pojavu znakov hiperstimulacije jajčnikov, kot je koncentracija estradiola >5.500 pg/ml (20.000 pmol/l) in/ali je vseh foliklov 30 ali več, priporoča opustitev dajanja hCG, bolnici pa naj se svetuje vzdržnost od spolnih odnosov ali uporaba mehanskih kontracepcijskih metod vsaj 4 dni.
The pH of the solution is 7.0 ± 0.3, its osmolality 250-400 mOsm/kg. 
pH raztopine je 7,0 ±0,3 in osmolalnost je 250-400 mOsm/kg.
CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT 250 micrograms/0.5 mL 
VSEBINA, IZRAŽENA Z MASO, PROSTORNINO ALI ŠTEVILOM ENOT 250 mikrogramov/0,5 ml
There is no indication for the use of Ovitrelle during pregnancy. 
Za uporabo zdravila Ovitrelle med nosečnostjo ni indikacij.
0.5 mL of solution in a pre-filled syringe (type I glass) with a plunger stopper (halobutyl rubber) and plunger (plastic), and with a needle for injection (stainless) - pack of 1. 
0,5 ml raztopine v napolnjeni injekcijski brizgi (steklo tip I) z batnim zamaškom (halobutilna guma) in batom (plastičnim) ter injekcijsko iglo (nerjavečo) - pakiranje po 1.
The following dose regimen should be used: 
Zdravilo se mora uporabljati po naslednji shemi odmerjanja:
Ask your pharmacist how to throw away medicines no longer used. 
O načinu odstranjevanja zdravila, ki ga ne uporabljate več, se posvetujte s farmacevtom.
• Ovitrelle is intended to be given by injection under the skin (subcutaneously). 
• Zdravilo Ovitrelle je namenjeno injiciranju pod kožo (subkutano).
In assisted reproductive techniques, there is an increased risk of OHSS with a serum estradiol > 3,000 pg/mL (11,000 pmol/L) and 18 or more follicles of 11 mm or more in diameter. 
Pri postopkih asistirane reprodukcije je tveganje za OHSS povečano pri serumski koncentraciji estradiola >3.000 pg/ml (11.000 pmol/l) in 18 ali več foliklih s premerom 11 mm ali več.
• The OHSS may become severe with clearly enlarged ovaries, decreased urine production, weight gain, difficulty in breathing and possible fluid accumulation in your stomach or chest. 
• OHSS lahko postane resen z izrazito povečanimi jajčniki, zmanjšanim nastajanjem urina, s pridobivanjem telesne mase, težavami dihanja in morebitnim nabiranjem tekočine v trebuhu ali prsnem košu.
Please note: alcohol swabs and sharps disposal container are not provided in the pack. 
Ne pozabite: alkoholne blazinice in vsebnik za odlaganje ostrih odpadkov niso priloženi pakiranju.
In women, chorionic gonadotropin acts as a surrogate luteinising hormone surge that triggers ovulation. 
Pri ženskah, deluje horionski gonadotropin kot nadomestek za porast luteinizirajočega hormona, ki sproži ovulacijo.
The rate of miscarriage, in both anovulatory patients and women undergoing assisted reproductive techniques, is higher than that found in the normal population but comparable with the rates observed in women with other fertility problems. 
Delež spontanih splavov je tako pri bolnicah brez ovulacije in ženskah v postopku asistirane reprodukcije, večji kot pri zdravi populaciji, vendar primerljiv z deležem spontanih splavov pri ženskah, ki imajo druge težave s plodnostjo.
Once you have finished your injection, immediately discard the empty syringe in a sharps container. 
Ko injiciranje končate, prazno brizgo z iglo takoj vrzite v posodo za ostre odpadke.
• If you administer Ovitrelle to yourself, please carefully read and follow the separate 
• Če si boste zdravilo Ovitrelle dajali sami, vas prosimo, da natančno preberete posebna
• Screw the threaded tip of the Ovitrelle pre-filled pen into the outer needle cap until you feel a light resistance. 
• Zasučite navojno konico zdravila Ovitrelle napolnjen injekcijski peresnik v zunanji pokrovček igle, dokler ne začutite rahlega upora.
• After a minimum of 5 seconds, pull the needle out of the skin while keeping the dose setting knob pressed down (3). 
• Po vsaj 5 sekundah izvlecite iglo iz kože in še vedno držite gumb za nastavitev odmerka navzdol
* recombinant human chorionic gonadotropin, r-hCG produced in Chinese hamster ovary (CHO) cells by recombinant DNA technology. 
*rekombinanti humani horiogonadotropin, r-hCG, pridobljen iz celic jajčnika kitajskega hrčka (Chinese hamster ovary - CHO) s tehnologijo rekombinantne DNA.
When undergoing Assisted Reproductive Techniques or stimulation of your ovaries to produce eggs, you are more likely to have a miscarriage than the average woman. 
Če ste v postopku asistirane reprodukcije ali stimulacije jajčnikov za nastajanje jajčec, je bolj verjetno, da boste imeli spontani splav, kot druge ženske.
Ovitrelle 250 micrograms solution for injection may be stored at room temperature (at or below +25°C) for up to 30 days without being refrigerated again during this period, and must be discarded if not used during these 30 days. 
Zdravilo Ovitrelle 250 mikrogramov raztopino za injiciranje lahko shranjujete pri sobni temperaturi (pri ali pod +25 °C) do 30 dni, brez ponovnega shranjevanja v hladilniku v tem času in jo morate zavreči, če je ne uporabite v teh 30 dneh.
Driving and using machines It is not expected that Ovitrelle will affect your ability to drive and use machines. 
Vpliv na sposobnost upravljanja vozil in strojev Ni pričakovano, da bi zdravilo Ovitrelle vplivalo na vašo sposobnost upravljanja vozil ali strojev.
• if you are allergic to choriogonadotropin alfa or any of the other ingredients of this medicine 
• če ste alergični na horiogonadotropin alfa ali katero koli sestavino tega zdravila (navedeno v poglavju 6).
Firmly pinch the skin together and insert the needle for injection at a 45° to 90° angle using a dart-like motion. 
Kožo trdno stisnite skupaj in iglo zabodite pod kotom 45° do 90° z gibom, podobnim metu sulice.
It shares the amino acid sequence with urinary hCG. Chorionic gonadotropin binds on the ovarian theca (and granulosa) cells to a transmembrane receptor shared with the luteinising hormone, the LH/CG receptor. 
Ima enako zaporedje aminokislin kot iz urina pridobljeni hCG. Horionski gonadotropin se na celicah teke (in granuloze) jajčnikov veže na transmembranski receptor LH/CG, ki je skupen luteinizirajočemu hormonu in hCG.
Other medicines will be given first to bring about the growth of several follicles. 
V teh postopkih najprej dajemo druga zdravila, da se doseže rast in razvoj več foliklov.
Ovitrelle is indicated in the treatment of: 
Zdravilo Ovitrelle je indicirano za zdravljenje:
• Your doctor or nurse will show you how to use the Ovitrelle pre-filled syringe to inject the medicine. 
• Vaš zdravnik ali medicinska sestra vam bosta pokazala, kako uporabiti napolnjen injekcijski peresnik zdravila Ovitrelle, da si injicirate zdravilo.
It is available as a single pre-filled syringe (pack of 1). 
Na voljo je kot enkratna napolnjena injekcijska brizga (škatlica z 1 napolnjeno injekcijsko brizgo).
Warning: Please read these instructions for use before using your Ovitrelle pre-filled pen. 
Opozorilo: Ta navodila preberite pred uporabo zdravila Ovitrelle napolnjen injekcijski peresnik.
What Ovitrelle is and what it is used for What do you need to know before you use Ovitrelle How to use Ovitrelle 
Kaj je zdravilo Ovitrelle in za kaj ga uporabljamo Kaj morate vedeti, preden boste uporabili zdravilo Ovitrelle Kako uporabljati zdravilo Ovitrelle Možni neželeni učinki
• Adult women undergoing superovulation prior to assisted reproductive techniques such as in vitro fertilisation (IVF): Ovitrelle is administered to trigger final follicular maturation and luteinisation after stimulation of follicular growth, 
• Odraslih žensk, ki so v postopku sprožitve superovulacije pred postopki asistirane reprodukcije, kot je npr. in vitro oploditev (IVF): zdravilo Ovitrelle se uporablja za sprožitev dokončnega folikelskega dozorevanja in luteinizacije po stimulaciji folikelske rasti.
If you administer Ovitrelle to yourself, please carefully read the following instructions: Wash your hands. 
Če si boste zdravilo Ovitrelle dajali sami, vas prosimo, da natančno preberete naslednja navodila:
PHARMACEUTICAL FORM AND CONTENTS 1 pre-filled syringe with 0.5 mL solution for injection 
FARMACEVTSKA OBLIKA IN VSEBINA 1 napolnjena injekcijska brizga z 0,5 ml raztopine za injiciranje
Pregnancy tests 
Test nosečnosti
• Primary ovarian failure 
• primarna insuficienca jajčnikov,
When using Ovitrelle, you have a higher risk of being pregnant with more than one child at the same time (‘multiple pregnancy', usually twins) than if you conceived naturally. 
Pri ženskah, ki uporabljajo zdravilo Ovitrelle, je tveganje za nosečnost z več otroki hkrati (večplodno nosečnost, običajno dvojčki) pogostejše kot pri ženskah, ki naravno zanosijo.
MARKETING AUTHORISATION NUMBER(S) EU/1/00/165/008 
ŠTEVILKA DOVOLJENJA ZA PROMET EU/1/00/165/008
To minimise the risk of OHSS, ultrasonographic assessments of follicular development and/or determination of serum estradiol levels should be performed prior to treatment and at regular intervals during treatment. 
Za zmanjšanje tveganja OHSS je treba pred zdravljenjem in nato v rednih časovnih presledkih opraviti ultrazvočni pregled folikularnega razvoja in/ali določiti koncentracije estradiola v serumu.
• Once you have finished your injection, dispose of the used needle safely. 
• Ko ste končali z injiciranjem, varno zavrzite uporabljeno iglo.
The risk of multiple pregnancy is reduced if the usual dose of Ovitrelle is used, and if you are monitored closely throughout your treatment cycle (e.g. blood tests for estradiol levels and ultrasound). 
Vaše tveganje za večplodno nosečnost se zmanjša, če uporabljate običajni odmerek zdravila Ovitrelle in vas celotni ciklus zdravljenja skrbno nadzirajo (npr. z določevanjem ravni estradiola v krvi in ultrazvokom).
The risk of OHSS is reduced if the usual dose of Ovitrelle is used, and if you are monitored closely throughout your treatment cycle (e.g. blood tests for estradiol levels and ultrasound). 
Vaše tveganje za OHSS se zmanjša, če uporabljate običajni odmerek zdravila Ovitrelle in če vas celotni ciklus zdravljenja skrbno nadzirajo (npr. z določevanjem ravni estradiola v krvi in ultrazvokom).
• Ovitrelle comes as a clear, colourless to slightly yellow liquid for injection in a pre-filled pen. 
• Zdravilo Ovitrelle je bistra, brezbarvna dorahlo rumena tekočina za injiciranje v napolnjem injekcijskem peresniku.
3 mL cartridge (type I glass, with a bromobutyl rubber plunger stopper and an aluminium crimp cap with bromobutyl rubber) preassembled in a pre-filled pen. 
3 ml vložek (steklo tip I z bromobutilnim batnim zamaškom in aluminijasto zaporko z bromobutilno gumo), sestavljeno v napolnjenem injekcijskem peresniku.
How to use Ovitrelle 
Kako uporabljati zdravilo Ovitrelle
• if you have cancer of your ovaries, womb or breast 
• če so vam odkrili raka na jajčniku, maternici ali dojki
Gently turn the dose setting knob clockwise until you see a dot (●) in the dose display. 
Previdno zasukajte gumb za nastavitev odmerka v smeri urinega kazalca, dokler v prikazu odmerka ne vidite pike (●).
• Ovarian, uterine or mammary carcinoma 
• karcinom jajčnika, maternice ali dojke
Before the treatment is started, your and your partner's fertility should be evaluated by a doctor experienced in the treatment of fertility problems. 
Pred začetkom zdravljenja mora zdravnik z izkušnjami v zdravljenju težav s plodnostjo oceniti vašo plodnost in plodnost vašega partnerja.
• The pen is for subcutaneous injection only. 
• Injekcijski peresnik je samo za subkutano injiciranje.
6.1 Check that the dose display shows ‘0' 
6.1 Preverite, da je v prikazu odmerka številka "0"
Headache Vascular disorders Very rare: 
Žilne bolezni Zelo redki:
Uncommon: Depression, irritability, restlessness Nervous system disorders 
depresija, razdražljivost, nemir Bolezni živčevja Pogosti:
• Tumours of the hypothalamus or pituitary gland 
• tumorji hipotalamusa ali hipofizne žleze
MARKETING AUTHORISATION NUMBER(S) EU/1/00/165/007 
ŠTEVILKA DOVOLJENJA ZA PROMET EU/1/00/165/007
What Ovitrelle looks like and contents of the pack 
Izgled zdravila Ovitrelle in vsebina pakiranja
Following administration, Ovitrelle may interfere for up to ten days with the immunological determination of serum or urinary hCG, potentially leading to a false positive pregnancy test. 
Vpliv na rezultate testiranja v serumu ali urinu Po dajanju lahko zdravilo Ovitrelle do deset dni vpliva na imunološko določanje serumskega/urinskega hCG, kar lahko povzroči lažno pozitiven nosečnostni test. Bolnice je treba na to opozoriti.
There is no clinical experience with Ovitrelle in the treatment of other conditions (such as corpus luteum insufficiency or male conditions); therefore, Ovitrelle is not indicated in these conditions. 
Kliničnih izkušenj z zdravilom Ovitrelle pri zdravljenju drugih stanj (kot je insuficienca rumenega telesca ali stanja pri moškem) ni.
• It is supplied in packs of 1 pre-filled pen and 1 injection needle. 
• Na voljo je kot pakiranje z 1 napolnjenim injekcijskim peresnikom in 1 injekcijsko iglo.
• Ovarian enlargement or cyst due to reasons other than polycystic ovarian disease 
• povečanje ali cista jajčnika, ki ni posledica policistične bolezni jajčnikov
Thromboembolism (both in association with and separate from OHSS) Gastrointestinal disorders 
trombembolizem (tako v povezavi z OHSS in nepovezano z njim) Bolezni prebavil
May be stored at or below +25°C for up to 30 days without being refrigerated again during this period and must be discarded if not used during these 30 days. 
Zdravilo lahko shranjujete pri temperaturi do +25 °C do 30 dni, brez ponovnega shranjevanja v hladilniku v tem času, in ga morate zavreči, če ga ne uporabite v teh 30 dneh.
The principal pharmacodynamic activity in women is oocyte meiosis resumption, follicular rupture (ovulation), corpus luteum formation and production of progesterone and estradiol by the corpus luteum. 
Glavno farmakodinamično delovanje pri ženskah je ponoven pojav meioze oocitov, ruptura folikla (ovulacija), tvorba rumenega telesca in izločanje progesterona in estradiola iz rumenega telesca.
dose setting knob dose display plunger piston reservoir holder threaded needle connector pen cap peel-off seal tab removable needle inner needle shield 10. outer needle cap 11. alcohol swabs 12. sharps disposal container 
gumb za nastavitev odmerka prikaz odmerka potiskalo bata prostor za tekočino navojni priključek za iglo pokrovček injekcijskega peresnika jeziček, ki se odlepi odstranljiva injekcijska igla notranji ščitnik igle 10. zunanji pokrovček igle 11. alkoholne blazinice 12. vsebnik za odlaganje ostrih odpadkov
Pregnancy outside of the womb (an ectopic pregnancy) may occur in women with damaged fallopian tubes (the tubes which carry the egg from the ovary to the womb). 
Nosečnost zunaj maternice (zunajmaternična nosečnost) se lahko pojavi pri ženskah s poškodovanimi jajcevodi.
If you do not see a tiny drop(s) of fluid at or near the tip: 
Če prvič ne opazite drobnih kapelj na ali blizu konice igle:
Inject the solution by pushing gently on the plunger. 
Raztopino injicirajte z rahlim potiskanjem bata.
5.4 Inject the dose as you were trained to do by your doctor or nurse 
5.4 Injicirajte odmerek, kot vas je poučil vaš zdravnik ali medicinska sestra
Since infertile women undergoing ART, and particularly IVF, often have tubal abnormalities, the incidence of ectopic pregnancies might be increased. 
Ker imajo neplodne ženske, ki se zdravijo s postopki asistirane reprodukcije, zlasti oploditve in vitro, pogosto abnormalnosti jajcevodov, je lahko incidenca zunajmaterničnih nosečnosti večja.
Mild or moderate OHSS 
blag do zmeren OHSS
• Do not push or pull the dose setting button while you turn it. 
• Gumba za nastavitev odmerka med sukanjem ne pritiskajte in ne vlecite.
Patients undergoing ovarian stimulation are at an increased risk of developing OHSS due to multiple follicular development. 
Sindrom hiperstimulacije jajčnikov (Ovarian Hyperstimulation Syndrome - OHSS) Pri bolnicah, ki so v postopku stimulacije jajčnikov, je povečano tveganje za razvoj OHSS zaradi razvoja več foliklov.
• Each pre-filled syringe is for single use only. 
• Vsaka napolnjena injekcijska brizga je samo za enkratno uporabo.
Multiple pregnancies and specific characteristics of couples with fertility problems (e.g. age) may also be associated with an increased chance of birth defects. 
Z večjo možnostjo prirojenih okvar so lahko povezane tudi večplodne nosečnosti in specifične značilnosti parov, ki imajo težave s plodnostjo (npr. zaradi starosti).
This medicine may increase your risk of developing OHSS. 
Sindrom hiperstimulacije jajčnikov (Ovarian Hyperstimulation Syndrome - OHSS) To zdravilo lahko poveča tveganje za razvoj OHSS.
Within its shelf-life, the solution may be stored at or below 25°C for up to 30 days without being refrigerated again during this period. 
V času roka uporabnosti lahko raztopino shranjujete pri temperaturi do 25 °C do 30 dni, brez ponovnega shranjevanja v hladilniku v tem času.
• Inject Ovitrelle as your doctor or nurse taught you. 
• Zdravilo Ovitrelle si injicirajte, kot vas je naučil vaš zdravnik ali medicinska sestra.
This shows that the complete dose was delivered. 
To pomeni, da ste odmerek injicirali v celoti.
Mild reversible skin reactions manifesting as rash Reproductive system and breast disorders Common: 
blaga prehodna kožna reakcija v obliki izpuščaja Motnje reprodukcije in dojk Pogosti:
Immediately inject the solution: Your doctor or nurse will have already advised you where to inject (e.g. tummy, front of thigh). 
Zdravnik ali medicinska sestra sta vas že poučila kam si dati injekcijo (npr. v trebuh, sprednji del stegna).
Other medicines will be given first to develop and ripen the follicles. 
Najprej dajemo druga zdravila, da se doseže rast in razvoj foliklov.
• After the injection, dispose of the used needle safely, and discard the pen. 
• Po vsakem injiciranju varno odstranite uporabljeno iglo in zavrzite peresnik.
Nonclinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity and genotoxicity. 
Predklinični podatki na osnovi običajnih študij farmakološke varnosti, toksičnosti pri ponavljajočih odmerkih in genotoksičnosti ne kažejo posebnega tveganja za človeka.
Press the dose setting knob as far as it will go. A tiny drop of liquid will appear at the top of the needle; this shows that your pre-filled pen is ready for injection. 
Na konici igle se mora prikazati majhna kaplja tekočine, kar pomeni, da je napolnjen injekcijski peresnik pripravljen na injiciranje.
Ovarian hyperstimulation syndrome may become a serious medical event characterised by large ovarian cysts, which are prone to rupture, weight gain, dyspnoea, oliguria or the presence of ascites within a clinical picture of circulatory dysfunction. 
Sindrom hiperstimulacije jajčnikov se lahko razvije v resen zaplet, za katerega so značilne velike ciste na jajčnikih, nagnjene k rupturi, povečanje telesne mase, dispneja, oligurija ali pojav ascitesa v klinični sliki disfunkcije obtočil.
Uncommon: Severe OHSS, breast pain General disorders and administration site conditions Common: 
hud OHSS, boleče dojke Splošne težave in spremembe na mestu aplikacije Pogosti:
Tiredness, injection site reactions. 
utrujenost, reakcije na mestu injiciranja
Pack of 1 pre-filled pen and 1 injection needle. 
Pakiranje z enim napolnjenim injekcijskim peresnikom in 1injekcijsko iglo.
What Ovitrelle contains 
Kaj vsebuje zdravilo Ovitrelle
QUALITATIVE AND QUANTITATIVE COMPOSITION Each pre-filled syringe contains 250 micrograms choriogonadotropin alfa* (equivalent to approximately 6,500 IU) in 0.5 mL solution. 
KAKOVOSTNA IN KOLIČINSKA SESTAVA Ena napolnjena injekcijska brizga vsebuje 250 mikrogramov horiogonadotropina alfa* (kar ustreza približno 6.500 i.e.) v 0,5 ml raztopine.
5.1 Choose the injection site in the area your doctor or nurse has told you to give the injection. 
5.1 Izberite mesto, kamor boste dali injekcijo na predelu, ki vam ga je svetoval zdravnik ali medicinska sestra.
In anovulation, the risk of OHSS is increased by a serum estradiol level > 1,500 pg/mL (5,400 pmol/L) and more than 3 follicles of 14 mm or more in diameter. 
Pri ženskah brez ovulacije je tveganje za sindrom hiperstimulacije jajčnikov povečano, če imajo serumsko koncentracijo estradiola >1.500 pg/ml (5.400 pmol/l) in več kot 3 folikle s premerom 14 mm ali več.